Showing results (791-800 of 5,687) with videos related to

Sort By:
Pageof 569
The Oncologist|August 14, 2014
Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancerNaoki Hayashi, Ganiraju C Manyam, Ana M Gonzalez-Angulo, et al.
The Oncologist|January 22, 2013
Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomyXingxing Chen, Xiaoli Yu, Jiayi Chen, et al.
The Oncologist|May 10, 2013
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experienceJason E Faris, Lawrence S Blaszkowsky, Shaunagh McDermott, et al.
The Oncologist|April 26, 2013
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human useElias Péan, Beatriz Flores, Ian Hudson, et al.
The Oncologist|April 26, 2013
BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical managementNoralane M Lindor, David E Goldgar, Sean V Tavtigian, et al.
The Oncologist|May 8, 2013
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reportingScott D Ramsey, Sean D Sullivan, Shelby D Reed, et al.
The Oncologist|May 8, 2013
Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopeciaManon M C Komen, Carolien H Smorenburg, Corina J G van den Hurk, et al.
The Oncologist|April 12, 2013
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancerJennifer K Litton, Carla L Warneke, Karin M Hahn, et al.
The Oncologist|April 12, 2013
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancerMartin H Cohen, Huanyu Chen, Stacy Shord, et al.
The Oncologist|April 13, 2013
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin, Kimmie Ng, Andrew X Zhu, et al.
Pageof 569